Drugs / AZD9550
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07546760 | Mar 2026 → Feb 2027 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07013643 | Jun 2025 → Jul 2027 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT05848440 | May → Nov 2023 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06151964 | Sep 2023 → Jan 2027 expected | morbid obesity | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07017179 | May 2025 → Oct 2026 expected | obesity disorder | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06862791 | Feb 2025 → May 2026 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9550 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05848440 ↗ |
| Action | Activate | “AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist.” NCT06151964 ↗ |
| Modality | Other / unclassified | “AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist.” NCT06151964 ↗ |
| Route | Subcutaneous | “administered AZD9550 subcutaneously” NCT05848440 ↗ |